prophylaxi
high
dose
neutral
antibodi
typic
offer
protect
challeng
virus
produc
acut
infect
studi
investig
abil
neutral
human
monoclon
antibodi
protect
ebola
viru
rhesu
macaqu
antibodi
previous
shown
fulli
protect
guinea
pig
infect
four
rhesu
macaqu
given
mgkg
neutral
human
monoclon
antibodi
intraven
challeng
plaqueform
unit
ebola
viru
follow
second
dose
mgkg
antibodi
challeng
control
anim
expos
viru
absenc
antibodi
treatment
passiv
transfer
neutral
human
monoclon
antibodi
fail
protect
macaqu
challeng
ebola
viru
also
minim
effect
explos
viral
replic
follow
infect
show
inabl
antibodi
impact
infect
due
neutral
escap
appear
ebola
viru
mechan
infect
propag
vivo
macaqu
uniqu
insensit
even
high
concentr
neutral
antibodi
editor
note
potenti
efficaci
preand
postexposur
prophylaxi
ebola
viru
infect
well
fundament
import
question
whether
neutral
bodi
import
ebola
viru
resist
address
relat
manuscript
issu
plo
pathogen
pleas
see
doi
feldmann
et
al
passiv
transfer
rel
high
concentr
neutral
antibodi
protect
challeng
rang
virus
anim
model
human
protect
case
form
steril
immun
ie
viral
replic
observ
follow
challeng
case
eg
replic
observ
protect
diseas
achiev
presum
neutral
antibodi
suffici
blunt
infect
cell
innat
immun
resolv
infect
might
expect
passiv
neutral
antibodi
would
effect
challeng
acut
virus
mani
acut
viral
infect
resolv
even
absenc
neutral
antibodi
blunt
effect
passiv
antibodi
would
provid
time
develop
effect
cellular
immun
respons
contrast
chronic
virus
may
present
greater
challeng
passiv
antibodi
sinc
absenc
steril
immun
window
opportun
viru
establish
chronic
infect
cellular
immun
mobil
ebola
viru
ebov
caus
sever
acut
infect
human
infect
ebola
zair
strain
zair
ebolaviru
zebov
produc
mortal
rang
death
gener
occur
around
follow
appear
symptom
singl
report
describ
use
convalesc
sera
treat
ebov
infect
howev
patient
report
may
alreadi
worst
stage
diseas
clear
serum
antibodi
respons
recoveri
neutral
antibodi
titer
survivor
ebov
infect
tend
rather
low
although
isol
neutral
human
monoclon
antibodi
mab
good
potenc
convalesc
individu
abil
passiv
antibodi
protect
ebov
investig
number
anim
model
guinea
pig
mous
model
use
ebov
serial
passag
adapt
replic
respect
anim
highli
lethal
protect
demonstr
guinea
pig
model
use
neutral
hors
sheep
goat
immunoglobulin
g
igg
ebov
human
antiebov
gp
mab
igg
antibodi
neutral
zebov
kikwit
inhibitori
concentr
ic
lgml
ic
lgml
vero
cell
ic
approxim
lgml
ic
lgml
primari
human
monocytesmacrophag
show
administ
subcutan
dosag
mgkg
h
challeng
antibodi
protect
robust
zebov
challeng
plaqueform
unit
pfu
guinea
pig
model
macaqu
provid
model
ebov
infect
like
closer
human
infect
human
viru
use
directli
macaqu
without
need
adapt
cours
diseas
mirror
seen
human
cynomolgu
macaqu
macaca
fasciculari
zebov
infect
produc
mortal
rate
death
occur
follow
infect
pfu
rhesu
macaqu
macaca
mulatta
zebov
produc
mortal
death
occur
infect
pfu
contrast
guinea
pig
experi
passiv
transfer
polyclon
equin
neutral
igg
describ
provid
minor
benefit
form
slight
delay
onset
viremia
day
day
follow
zebov
challeng
cynomolgu
monkey
signific
reduct
mortal
observ
howev
protect
ebov
primat
observ
low
dose
challeng
model
thu
neutral
equin
igg
protect
baboon
ld
lethal
dose
zebov
challeng
igg
given
h
infect
serum
contain
high
neutral
antibodi
titer
similarli
neutral
ovin
serum
protect
baboon
ld
zebov
challeng
studi
abil
passiv
transfer
neutral
human
mab
protect
zebov
challeng
rhesu
macaqu
passiv
transfer
fail
protect
macaqu
challeng
zebov
furthermor
minim
effect
explos
viral
replic
follow
infect
show
elisa
antibodi
present
high
level
serum
monkey
neutral
escap
respons
resist
viru
antibodi
prophylaxi
evalu
whether
iggl
could
protect
ebola
viru
infect
nonhuman
primat
anim
model
antibodi
passiv
transfer
rhesu
macaqu
follow
challeng
zebov
kikwit
isol
h
later
protect
viru
challeng
neutral
antibodi
naiv
anim
often
requir
high
dose
antibodi
therefor
use
high
dose
mgkg
close
maximum
practic
achiev
addit
gave
second
bolu
mgkg
day
follow
infect
result
four
antibodytr
anim
show
steadi
increas
plasma
viremia
pfuml
day
figur
level
plasma
viremia
close
parallel
seen
control
anim
typic
seen
histor
control
second
bolu
antibodi
given
day
appear
impact
upon
rate
increas
plasma
viru
figur
three
treat
anim
euthan
moribund
day
post
infect
fourth
treat
anim
show
decreas
plasma
viral
load
peak
surviv
day
becom
moribund
euthan
although
monkey
less
sever
symptom
anim
studi
conclud
anim
suffer
diseas
due
zebov
evidenc
exampl
copiou
ebola
viru
antigen
lung
see
serum
antibodi
load
measur
viru
challeng
day
challeng
antibodi
boost
day
elisa
design
detect
human
antibodi
bound
immobil
zebov
glycoprotein
serum
antibodi
level
day
approxim
rang
lgml
tabl
figur
plasma
viremia
macaqu
challeng
zebov
shown
measur
viremia
log
pfu
per
ml
four
antibodytr
monkey
one
untreat
control
anim
ehd
day
plasma
plaqu
assay
describ
materi
method
mgkg
human
antibodi
given
intraven
four
rhesu
macaqu
challeng
pfu
intramusculari
zebov
kikwit
isol
ab
antibodi
plo
pathogen
wwwplospathogensorg
januari
volum
issu
antiebola
antibodi
activ
vivo
ebola
viru
one
fear
human
pathogen
mortal
approach
extrem
rapid
diseas
cours
lead
death
within
day
infect
antibodi
abl
inhibit
viral
infect
cultur
neutral
antibodi
typic
prevent
viral
infect
anim
human
present
prior
infect
suffici
concentr
neutral
antibodi
may
provid
passiv
administr
induc
vaccin
previous
shown
human
neutral
antibodi
protect
guinea
pig
ebola
viru
howev
show
antibodi
protect
monkey
ebola
viru
surprisingli
appear
littl
impact
upon
rapid
cours
infect
despit
present
high
level
blood
monkey
conclud
administ
antibodi
prior
immedi
follow
exposur
ebola
viru
exampl
accid
research
set
bioterrorist
attack
unlik
effect
prevent
diseas
recent
success
protect
monkey
ebola
viru
vaccin
may
independ
antibodi
like
critic
depend
cooper
antibodi
cellular
immun
two
control
monkey
ehd
untreat
challeng
neg
monkey
neither
treat
challeng
similar
background
level
reactiv
glycoprotein
antihuman
antibodi
treat
monkey
treatment
dose
typic
produc
serum
mab
concentr
anim
order
lgml
inject
sinc
neutral
titer
ic
zebov
order
lgml
depend
upon
target
cell
presenc
complement
concentr
anim
time
challeng
first
day
expect
greater
order
ic
concentr
typic
provid
steril
immun
challeng
number
virus
one
formal
possibl
neutral
antibodi
littl
effect
cours
infect
treat
monkey
rapid
emerg
neutral
escap
mutant
accordingli
viru
isol
select
plasma
day
monkey
day
monkey
virus
sensit
essenti
neutral
observ
vitro
lgml
plaqu
assay
see
materi
method
use
vero
target
cell
order
gain
better
understand
differ
patholog
control
antibodytr
anim
level
viru
differ
organ
survey
postmortem
viral
level
liver
spleen
kidney
adren
gland
lung
mesenter
inguin
lymph
node
high
pfug
control
three
four
treat
anim
tabl
howev
monkey
surviv
much
longer
anim
day
show
major
histopatholog
differ
infect
monkey
norm
zebov
infect
rel
low
viral
level
observ
organ
none
liver
spleen
adren
gland
addit
larg
immunoreact
monocyt
found
blood
monkey
figur
typic
smaller
immunoreact
monocyt
seen
zebov
infect
presenc
larg
immunoreact
monocyt
may
simpli
reflect
uptak
antibodyco
virion
via
fc
receptor
subsequ
viral
clearanc
howev
interest
note
previou
studi
implic
mononuclear
phagocyt
vehicl
transport
filoviru
particl
specif
organ
liver
spleen
viru
particl
could
remain
infecti
follow
fc
receptormedi
uptak
subset
cell
compar
dcsign
mediat
uptak
dendrit
cell
cours
diseas
monkey
might
repres
net
result
inhibit
neutral
enhanc
antibodymedi
cellular
uptak
interestingli
monkey
fare
somewhat
better
other
lack
viru
liver
spleen
show
presenc
larg
immunoreact
monocyt
suggest
lower
fc
receptormedi
uptak
viru
reduc
activ
mononuclear
phagocyt
system
describ
case
potent
neutral
human
monoclon
antibodi
administ
give
high
serum
concentr
shown
unabl
protect
macaqu
challeng
lethal
dose
zebov
antibodi
appear
littl
effect
cours
viru
replic
diseas
three
four
treat
anim
neutral
escap
appear
explain
lack
protect
observ
antibodi
one
anim
limit
infect
observ
macaqu
also
eventu
succumb
effect
viral
diseas
challeng
dose
pfu
use
correspond
amount
ebov
contain
rel
small
quantiti
fluid
order
infect
individu
given
high
titer
viru
typic
found
individu
order
pfuml
blood
exampl
therefor
challeng
dose
unreason
term
natur
exposur
viru
neg
result
passiv
antibodi
contrast
strongli
recent
success
prevent
ebov
infect
macaqu
vaccin
mean
neutral
antibodi
unimport
vaccin
protect
answer
question
must
await
studi
howev
plausibl
hypothesi
explain
data
would
still
allow
import
contribut
antibodi
vaccin
protect
hypothesi
would
argu
passiv
antibodi
unabl
complet
block
ebov
entri
cell
cell
infect
viru
replic
explos
contain
de
novo
gener
cellular
immun
respons
vaccin
hand
provid
memori
cell
rapidli
recruit
becom
effector
cell
limit
infect
certainli
although
mab
abl
provid
protect
diseas
follow
zebov
challeng
guinea
pig
model
immun
steril
viral
replic
note
sinc
pfu
ebov
lethal
dose
primat
failur
passiv
antibodi
achiev
steril
immun
may
critic
immunohistochemistri
discuss
give
intrigu
hint
uptak
antibodyco
virion
monocyt
may
possibl
role
play
cours
infect
follow
antibodi
treatment
note
howev
previou
vitro
studi
use
isol
human
monocytesmacrophag
find
evid
infectivityenhanc
antibodi
detail
vitro
vivo
investig
requir
firm
conclus
drawn
also
note
experi
carri
singl
neutral
monoclon
antibodi
possibl
favor
outcom
may
appar
combin
neutral
antibodi
even
combin
neutral
nonneutr
antibodi
howev
possibl
weigh
high
concentr
neutral
monoclon
antibodi
use
experi
efficaci
antibodi
guinea
pig
model
summari
inabl
high
concentr
neutral
antibodi
even
slow
viral
replic
infect
macaqu
remark
impli
mechan
infect
propag
virtual
insensit
antibodi
overal
result
suggest
monoclon
antibodi
prophylaxi
postexposur
prophylaxi
alon
unlik
effect
strategi
protect
ebov
exampl
follow
needlestick
accid
research
set
bioterrorist
attack
passiv
transfer
experi
mgkg
human
antibodi
given
intraven
rhesu
macaqu
weight
kg
challeng
day
pfu
intramuscularli
zebov
kikwit
isol
later
day
one
monkey
given
antibodi
treatment
anim
care
monitor
sign
diseas
ebola
viru
plasma
viremia
determin
day
serum
plaqu
assay
describ
investig
adher
guid
care
use
laboratori
anim
conduct
research
use
anim
unit
state
armi
medic
research
institut
infecti
diseas
usamriid
anim
facil
anim
care
use
program
accredit
associ
assess
accredit
laboratori
anim
care
intern
infecti
materi
anim
handl
maximumcontain
biosafeti
level
facil
usamriid
standard
oper
condit
antibodi
purif
iggl
produc
purifi
describ
parren
et
al
pure
determin
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
contain
iu
endotoxinml
determin
quantit
chromagen
limulu
amoebecyt
lysat
assay
biowhittak
cambrex
http
wwwcambrexcom
viremia
determin
plaqu
assay
plasma
viremia
viral
load
organ
determin
viru
titrat
convent
plaqu
assay
vero
cell
describ
elsewher
neutral
assay
sampl
dilut
eagl
minim
essenti
medium
emem
invitrogen
http
wwwinvitrogencom
heatinactiv
fetal
bovin
serum
fb
presenc
absenc
constant
dilut
mgml
thu
mgml
mgml
plasma
titrat
dilut
viremia
determin
count
pfu
vero
cell
monolay
cell
grown
confluenc
plate
given
ml
plasma
without
addit
titrat
sampl
incub
presenc
h
co
absorpt
cell
overlaid
ml
emem
contain
fb
mm
hepe
buffer
gentamicin
per
ml
agaros
plaqu
visibl
cell
remov
humidifi
incub
visual
plaqu
invert
phase
microscop
ml
neutral
red
final
concentr
sigmaaldrich
http
wwwsigmaaldrichcom
ad
well
addit
incub
plaqu
count
elisa
nuncimmuno
maxisorp
enzymelink
immunosorb
assay
elisa
plate
nunc
http
nuncbrandcom
coat
llwell
lgml
lectin
galanthu
nivali
sigmaaldrich
pb
incub
overnight
plate
block
phosphatebuff
salin
pb
contain
fb
h
well
wash
twice
wash
buffer
pb
contain
tween
sigmaaldrich
cell
transfect
mammalian
express
plasmid
code
transmembran
domaindelet
ebola
glycoprotein
supernat
cell
contain
mgml
total
protein
use
coat
well
h
room
temperatur
rt
block
solut
remov
elisa
plate
plate
wash
six
time
wash
buffer
monkey
sera
ad
dilut
dilut
buffer
pb
contain
bsa
tween
incub
rt
h
well
wash
six
time
secondari
antibodi
alkalin
phosphataseconjug
goat
antihuman
immunoglobulin
g
igg
f
portion
antibodi
pierc
http
wwwpiercenetcom
dilut
ad
incub
h
final
plate
wash
six
time
develop
one
tablet
phosphatas
substrat
typic
smaller
immunoreact
monocyt
seen
zebov
infect
immunohistochemistri
perform
describ
materi
method
sigmaaldrich
ml
alkalin
phosphatas
stain
buffer
ph
per
plate
assay
perform
per
manufactur
direct
plate
read
optic
densiti
nm
micropl
reader
molecular
devic
http
wwwmoleculardevicescom
min
ad
substrat
panel
normal
sera
run
time
assay
perform
immunohistochemistri
section
pretreat
dako
readi
use
proteinas
k
dako
http
wwwdakocom
min
rt
deparaffin
rehydr
seri
grade
ethanol
block
perform
dako
serumfre
protein
block
min
preantibodi
exposur
tissu
section
incub
overnight
primari
antibodi
use
equal
mixtur
mous
monoclon
antibodi
ebov
gp
alkalin
phosphataselabel
polym
dako
envis
system
alkalin
phosphatas
incub
section
min
color
develop
expos
tissu
acid
histomark
red
kikegaard
perri
laboratori
http
wwwkplcom
substrat
min
dark
counterstain
done
hematoxylin
posit
control
includ
archiv
ebovinfect
cynomolgu
tissu
neg
control
includ
replic
section
expos
antimarburg
viru
antibodi
uninfect
cynomolgu
macaqu
tissu
